The Peptide Surge: Counseling Guidance on GLP-1s, Compounded Therapies, and What Patients Want to Know

This FAQ was fact-checked by Mohammed Chammout, PharmD.

Peptide therapies have moved from the margins of medicine to the center of conversations, and patients are arriving at the pharmacy counter with questions that reflect that shift. The clinical success of glucagon-life peptide-1 (GLP-1) receptor agonists has reshaped chronic disease management across multiple specialties, while a wave of social media–driven interest in compounded peptides has created a parallel surge of curiosity, confusion, and misinformation among patients. Regulatory changes in early 2026 have added further complexity, prompting questions that range from the straightforward to the clinically nuanced.

Pharmacists, who are the most accessible health care professionals that patients encounter, are uniquely positioned to bridge the gap between headlines and evidence-based guidance. Pharmacists are able to offer practical answers to the questions that patients are most likely to bring to the table, and they have the power to offer counseling frameworks that can help address these needs.

Q1: What exactly are peptide therapies, and why are pharmacists seeing more questions about them?

Peptide therapies span a wide range of compounds, from rigorously studied, FDA-approved agents like semaglutide (Ozempic, Wegovy; Novo Nordisk) and tirzepatide (Zepbound, Mounjaro; Eli Lilly) to compounded peptides like BPC-157 and TB-500 that have limited human clinical trial data. What has changed is the pace and breadth of prescribing. GLP-1 receptor agonists are now being used across primary care, endocrinology, cardiology, and rheumatology, among other areas. Meanwhile, compounded peptides are drawing heightened patient interest following the February 2026 Department of Health and Human Services (HHS) announcement that about 14 of 19 previously restricted peptides would be reclassified from Category 2 back to Category 1 status, restoring a legal compounding pathway. Social media has amplified all of this, often without clinical nuance. Pharmacists are now among the most accessible touchpoints for patients trying to understand what these therapies are, which ones have real evidence behind them, and what risks they should know about.

Q2: Why does it seem like peptides are suddenly everywhere—in clinics, on social media, and at the pharmacy counter?

The surge in peptide interest is the product of several converging forces. On the clinical side, the success of GLP-1 receptor agonists demonstrating meaningful weight loss, cardiovascular risk reduction, and metabolic benefit in large-scale trials has shifted how medicine approaches chronic disease management. These drugs are peptides, and their success has opened the door to broader interest in peptide-based therapeutics across obesity medicine, cardiology, rheumatology, women's health, and beyond. When a class of molecules produces outcomes that older therapies couldn't match, both health care professionals and patients pay attention.

On the consumer side, social media has dramatically accelerated awareness and misinformation. Influencers, wellness podcasts, and direct-to-consumer peptide clinics have introduced millions of patients to compounds like BPC-157, TB-500, and various growth hormone secretagogues, often framed as tools for recovery, anti-aging, muscle preservation, or longevity, and this messaging frequently outpaces the evidence. Many patients arriving at the pharmacy counter have already self-researched a specific peptide and are looking for access, not necessarily an introduction.

The regulatory turbulence of recent years has added another layer. When the FDA moved 19 peptides to its Category 2 restricted compounding list in late 2023, it pulled a large portion of the legally compounded peptide market offline overnight. Patient demand did not disappear; instead, it migrated toward unregulated online vendors. The 2026 reclassification announcement reignited interest and generated a fresh wave of questions, many of which are based on incomplete or inaccurate reporting of what the policy change actually means.

Q3: Are peptides a new development in medicine, or are they a resurgence of something older?

Peptide therapeutics are not new. They represent one of the oldest and most productive areas of pharmaceutical development. Insulin, which was first isolated in 1921 and used therapeutically in 1922, is a peptide, as well as oxytocin, vasopressin, and many other foundational agents in modern medicine. What is new are the pace of innovation and the breadth of conditions that are now being targeted with peptide-based approaches.

Advances in drug delivery, formulation science, and molecular engineering have dramatically expanded what peptide therapies can do and how they can be administered. GLP-1 receptor agonists are a direct product of that innovation—agents designed to mimic and extend the action of naturally occurring gut hormones, now available in once-weekly injectable and oral formulations with clinical profiles that rival or exceed older drug classes.

What is emerging alongside the approved therapies is a much larger pipeline. Investigational approaches targeting lean body mass preservation during weight loss, dual and triple receptor agonists, and peptides aimed at inflammation, tissue repair, and immune modulation are all in varying stages of research. Some of these are years away from any regulatory decision. Others are being promoted to patients right now with minimal human evidence.

For pharmacists, understanding this distinction—between peptides with a robust regulatory and clinical record and those with promising preclinical data but limited human evidence—is foundational to effectively counsel patients who are seeking more information on peptides. The “peptide therapy” category is broad enough to include both semaglutide and a research-use–only vial from an online vendor, and patients deserve to understand that difference.

Q4: What did the February 2026 regulatory change actually mean? What does it not mean?

This is perhaps the most important counseling point pharmacists can make right now. The reclassification of peptides from Category 2 to Category 1 is a compounding regulatory designation. It governs whether licensed compounding pharmacies operating under Sections 503A or 503B may legally prepare a substance. It does not mean these peptides have been FDA-approved, and it does not establish proven efficacy or standardized dosing. Category 1 status means a substance can be compounded under interim policy while FDA review continues.

Patients are frequently conflating 3 very different categories:

1. FDA-approved peptide drugs, which are fully regulated and rigorously studied;
2. Category 1 compoundable peptides, which are legally preparable by licensed compounders—but are not FDA-approved—and have variable evidence;
3. and gray-market “research peptides,” which means they are unregulated, unverified, and often of unknown quality.

Pharmacists are well-positioned to help patients understand the difference and make informed decisions about where their product is actually coming from.

Q5: What are the most important safety and tolerability considerations for patients on long-term GLP-1 therapy?

As patients remain on GLP-1 therapies longer term, several underrecognized complications should receive routine attention from pharmacists:

• Nutritional compromise: Reduced caloric intake, nausea, and altered eating patterns increase the risk of protein, micronutrient, and hydration deficits over time. Pharmacists should screen for signs of inadequate nutritional intake and address supplement use proactively.
• Oral health: Patients frequently report dry mouth, altered taste, and reflux. Emerging evidence suggests that GLP-1 receptor agonists may affect salivary gland signaling, which can increase risk for dental caries and enamel erosion. Oral health counseling is rarely integrated into obesity medicine workflows but are worth addressing.
• Perioperative risk: Delayed gastric emptying associated with GLP-1 therapy raises aspiration risk in surgical patients. This is an area where pharmacist-to-prescriber communication can be clinically significant.
• Ophthalmologic monitoring: A transient worsening of diabetic retinopathy has been reported with rapid glycemic improvement, particularly in patients with preexisting eye disease, though evidence across large outcome trials remains mixed and inconclusive. Patients with diabetes should be reminded to maintain regular ophthalmology follow-up, especially early in therapy.
• Supplement and drug interactions: As patients seek over-the-counter and herbal products to manage adverse effects (AEs) like nausea, fatigue, hair loss, and muscle loss, pharmacists should screen for potential interactions and evaluate the evidence quality of what patients are taking.

Q6: How should pharmacists counsel patients who are curious about compounded peptides like BPC-157 or TB-500?

Start with the evidence picture, not just the legal picture. BPC-157 has extensive preclinical data across animal models, but only three small pilot studies in humans, none of which meet the standard for FDA drug approval.

TB-500 has no completed human randomized controlled trials. Reclassification does not change the underlying evidence base; it restores access to a regulated supply chain.

When patients ask, a reasonable counseling framework includes:

1. Avoid gray-market sources. Peptides sold online as “research use only” remain unregulated, frequently misrepresented, and of unverified quality. They are not equivalent to a prescription compounded peptide regardless of how they are labeled.
2. Wait for formal FDA publication. A policy announcement is not a rule change. Compounding pharmacies will need formal FDA guidance, verified raw material sourcing, and batch validation before resuming large-scale production.
3. Require physician supervision. Peptide protocols require medical evaluation, lab work, and ongoing monitoring. Dosing advice circulating on social media is not clinically validated.
4. Ask about pharmacy sourcing and standards. Reputable compounding pharmacies carry PCAB accreditation, comply with United States Pharmacopeia <795> and <797> standards, and can provide certificates of analysis with third-party purity verification. If a provider cannot document sourcing, that is a red flag.

Q7: What role can pharmacists play in long-term peptide management and where might the field be heading?

Pharmacists are trained to evaluate pharmacology, drug interactions, dose-response relationships, nutrition, hydration, and supplement use simultaneously. In a GLP-1 clinic or metabolic medicine setting, this creates a distinct clinical lens. Rather than adding therapies to manage AEs, pharmacists may help identify when slower titration, dose reduction, nutritional intervention, or targeted supportive care is the more appropriate path.

Clinical pharmacist-led GLP-1 programs are beginning to emerge in ambulatory care settings, and as the patient population expands to include pediatric, geriatric, and complex comorbidity cases, pharmacist involvement in multidisciplinary care teams continues to grow. There is also increasing discussion within the field about whether a formal board certification pathway in peptide therapeutics or metabolic medicine may eventually be warranted—a precedent that exists in oncology, critical care, nutrition support, and infectious disease.

In the near term, pharmacists who stay current on evolving clinical data, nutrition science, compounding regulations, and integrative medicine strategies will be better positioned to serve as clinical educators for both patients and prescribers. As patients continue to arrive at the pharmacy counter with questions shaped by social media headlines, that role has never been more needed.